<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Drugs Aging</journal-id><journal-id journal-id-type="iso-abbrev">Drugs Aging</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Drugs &amp; aging</journal-title></journal-title-group><issn pub-type="ppub">1170-229X</issn><issn pub-type="epub">1179-1969</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC5333645</article-id><article-id pub-id-type="pmcid-ver">PMC5333645.1</article-id><article-id pub-id-type="pmcaid">5333645</article-id><article-id pub-id-type="pmcaiid">5333645</article-id><article-id pub-id-type="manuscript-id">NIHMS532119</article-id><article-id pub-id-type="pmid">21812499</article-id><article-id pub-id-type="doi">10.2165/11592880-000000000-00000</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS532119</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA532119</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Systemic Therapies for Metastatic Renal Cell Carcinoma in Older Adults</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Pal</surname><given-names initials="SK">Sumanta K.</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Vanderwalde</surname><given-names initials="A">Ari</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hurria</surname><given-names initials="A">Arti</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Figlin</surname><given-names initials="RA">Robert A.</given-names></name><xref ref-type="aff" rid="A4">4</xref></contrib></contrib-group><aff id="A1"><label>1</label>Division of Genitourinary Malignancies, Department of Medical Oncology &amp; Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA</aff><aff id="A2"><label>2</label>Department of Medical Oncology &amp; Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA</aff><aff id="A3"><label>3</label>Department of Medical Oncology &amp; Experimental Therapeutics, Cancer Control and Population Sciences Program, and Cancer and Aging Research Program, City of Hope Comprehensive Cancer Center, Duarte, CA, USA</aff><aff id="A4"><label>4</label>Department of Medicine, Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA, USA</aff><author-notes><corresp id="FN1">Correspondence: Robert A. Figlin, Professor &amp; Director, Hematology-Oncology, Department of Medicine, Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, 8700 Beverly Blvd, AC 1085 North Tower, Los Angeles, CA, 90048, USA. <email>Robert.Figlin@cshs.org</email></corresp></author-notes><pub-date pub-type="ppub"><day>01</day><month>8</month><year>2011</year></pub-date><volume>28</volume><issue>8</issue><issue-id pub-id-type="pmc-issue-id">288644</issue-id><fpage>635</fpage><lpage>649</lpage><pub-history><event event-type="nihms-submitted"><date><day>27</day><month>07</month><year>2016</year></date></event><event event-type="pmc-release"><date><day>02</day><month>03</month><year>2017</year></date></event><event event-type="pmc-live"><date><day>02</day><month>03</month><year>2017</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-06-17 13:25:17.317"><day>17</day><month>06</month><year>2024</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms532119.pdf"/><abstract><p id="P1">The introduction of targeted therapies has radically changed the treatment paradigm for metastatic renal cell carcinoma (mRCC). However, multiple clinical dilemmas have emerged. For instance, limited data are available to juxtapose the safety and efficacy profile of targeted therapies between older and younger adults. Herein, pivotal trials of vascular endothelial growth factor (VEGF)- and mammalian target of rapamycin (mTOR)-directed therapies are assessed in the context of their implications in treating older adults with mRCC. In general, subset analyses from these pivotal studies suggest similar efficacy of targeted therapies amongst older adults. Aging is accompanied by a multitude of physiological changes, as well as an increased prevalence of co-morbidities. The age-related toxicity profiles of targeted agents for mRCC are detailed to provide a framework for the risks and benefits of these therapies in older adults. Ultimately, tools such as the Comprehensive Geriatric Assessment (CGA) that account for physiological (as opposed to chronological) age may prove useful in the evaluation and treatment of older adults with mRCC.</p></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>